abrdn Life Sciences Investors (HQL) to Distribute Quarterly Dividend of $0.62 on September 30th

abrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Tuesday, August 11th. Investors of record on Monday, August 24th will be paid a dividend of 0.62 per share on Wednesday, September 30th. This represents a c) dividend on an annualized basis and a yield of 11.7%. The ex-dividend date is Monday, August 24th.

abrdn Life Sciences Investors Price Performance

abrdn Life Sciences Investors stock opened at $21.23 on Thursday. The firm has a fifty day simple moving average of $19.19 and a two-hundred day simple moving average of $17.84. abrdn Life Sciences Investors has a twelve month low of $13.44 and a twelve month high of $21.32.

Institutional Investors Weigh In On abrdn Life Sciences Investors

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its stake in shares of abrdn Life Sciences Investors by 57.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 362,535 shares of the company’s stock worth $5,898,000 after buying an additional 132,098 shares during the period. LPL Financial LLC boosted its position in abrdn Life Sciences Investors by 20.0% during the 4th quarter. LPL Financial LLC now owns 448,846 shares of the company’s stock valued at $7,532,000 after buying an additional 74,787 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in abrdn Life Sciences Investors during the 4th quarter valued at $1,158,000. Raymond James Financial Inc. grew its holdings in abrdn Life Sciences Investors by 20.3% in the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company’s stock worth $4,816,000 after acquiring an additional 63,429 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in abrdn Life Sciences Investors by 24.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 209,681 shares of the company’s stock worth $3,254,000 after acquiring an additional 41,255 shares during the last quarter. Institutional investors own 32.21% of the company’s stock.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.